» Articles » PMID: 3922267

Long-term Oxygen Therapy Can Reverse the Progression of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

Overview
Specialty Pulmonary Medicine
Date 1985 Apr 1
PMID 3922267
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Sixteen patients with severe chronic obstructive pulmonary disease (COPD) (average values at the onset of O2 therapy: FEV1, 891 +/- 284 ml; PaO2, 50.2 +/- 6.6 mmHg; PaCO2, 51.0 +/- 6.4 mmHg) underwent 3 consecutive right heart catheterizations. The first was performed 47 +/- 28 months (T0) before the onset of long-term O2 therapy (LTO2). The second was performed just before the onset of LTO2 (T1). The third was performed after 31 +/- 19 months of LTO2 (T2). Oxygen therapy (15 to 18 h/day) was prescribed on the basis of usual criteria. From T0 to T1, PaO2 decreased from 59.3 +/- 9.4 to 50.2 +/- 6.6 mmHg, and mean pulmonary arterial pressure (Ppa) worsened from 23.3 +/- 6.8 to 28.0 +/- 7.4 mmHg (p less than 0.005). From T1 to T2, PaO2 was stable, whereas Ppa decreased from 28.0 +/- 7.4 to 23.9 +/- 6.6 mmHg (p less than 0.05). Pulmonary hypertension improved in 12 of the 16 patients. Before the onset of LTO2 (from T0 to T1), there was a yearly increase in Ppa of 1.47 +/- 2.3 mmHg, whereas during LTO2 a yearly decrease of 2.15 +/- 4.4 mmHg was observed, and the difference between these 2 values was highly significant. The changes in Ppa either from T0 to T1 or from T1 to T2 were not associated with concomitant changes in cardiac output or pulmonary capillary wedge pressure but were related to changes in pulmonary vascular resistance. These results suggest that LTO2 for 15 to 18 h/day can reverse the progression of pulmonary hypertension in a high percentage of patients with severe COPD, but that normalization of Ppa is rarely observed.

Citing Articles

Diagnosis and management of comorbid disease in COPD.

Cronin E, Cushen B Breathe (Sheff). 2025; 21(1):240099.

PMID: 40007528 PMC: 11851148. DOI: 10.1183/20734735.0099-2024.


Supplemental oxygen for pulmonary embolism (SO-PE): study protocol for a mechanistic, randomised, blinded, cross-over study.

Lyhne M, Liteplo A, Zeleznik O, Dudzinski D, Andersen A, Shokoohi H BMJ Open. 2024; 14(11):e091567.

PMID: 39532350 PMC: 11574393. DOI: 10.1136/bmjopen-2024-091567.


Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.

Lawrence A, Myall K, Mukherjee B, Marino P Life (Basel). 2024; 14(9).

PMID: 39337985 PMC: 11433497. DOI: 10.3390/life14091203.


Long-term oxygen therapy in precapillary pulmonary hypertension - SOPHA study.

Benjamin N, Echampati I, Harutyunova S, Eichstaedt C, Egenlauf B, Ulrich S Sci Rep. 2024; 14(1):22038.

PMID: 39327434 PMC: 11427660. DOI: 10.1038/s41598-024-70650-w.


Pulmonary hypertension associated with lung diseases.

Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E Eur Respir J. 2024; 64(4).

PMID: 39209469 PMC: 11525344. DOI: 10.1183/13993003.01200-2024.